Skip to main content
Clinical Trials/NCT03951792
NCT03951792CompletedNot Applicable

Time Longitudinal Study of the Microbiome in Colorectal Cancer Subjects

Mayo Clinic1 site in 1 country220 target enrollmentStarted: May 28, 2019Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
220
Locations
1
Primary Endpoint
DNA/RNA Biomarkers

Study Overview

Brief Summary

Researchers are trying to determine whether certain microbiome cause cancer or whether they are part of the microbiome in the gut due to the presence of cancer.

Detailed Description

The purpose of this research is to learn about how the gastrointestinal bacteria (microbiome) can contribute to colon cancer, and how it may change due to colon cancer. In addition, we are going to study the features of the microbiome that can help predict recovery after colon resection. To do this, we are going to compare the microbiome from subjects with colon cancer to subjects without colon cancer.

Study participation involves collection of stool samples before and after your surgery, as well as samples of residual (left-over) colon tissue from your surgery. We would also like to collect optional samples from your follow-up colonoscopy. You may be in the study for up to 5 years.

Study Design

Study Type
Observational
Observational Model
Case Control
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • 18 years of age or older
  • Patients undergoing bowel resection by any standard surgical approach.

Exclusion Criteria

  • Female that are pregnant
  • Currently receiving or have received pelvic cancer radiation therapy in the past 2 weeks.
  • Currently receiving or have received chemotherapy in the past 2 weeks.

Outcomes

Primary Outcomes

DNA/RNA Biomarkers

Time Frame: 5 years

Biomarkers will be defined by extracting DNA/RNA from tissue biopsies and stored for specific gene extractions.

Microbial 16S rDNA Biomarkers

Time Frame: 5 years

The samples will be used to partially (V3-V5 region) amplify the microbial 16S rDNA genes through a polymerase chain reaction (PCR). The PCR product will subsequently be purified and quantified before being sequenced. They will also be used for whole genome sequencing (WGS) and Methylation sequencing (Methyl-Seq). The RNA will be used for RNAseq.

Secondary Outcomes

  • Protein Measurements(5 years)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials